Our Ref: 52/2023 JANUARY 2023



Re: Your request made under the Freedom of Information Act 2000

Under the freedom of information (FOI) Act 2000, I would like to request the following information regarding your NHS Trusts/Boards:

What are your current skin cancer patient clinical pathway guidelines e.g., from initial patient symptoms in a
GP setting to specialist referral as well as treatment and follow-up procedures and protocol. Attached are
two outdated CCG (Clinical Commissioning Group) pathway guidelines for reference.

The current agreed pathway follows the criteria on the North Trent 2ww skin cancer pro- forma which primary care physicians should utilise when referring to secondary care. Referral are directly bookable on ERS at our three main sites. We offer 2ww assessment clinics and See and treat clinics, procedures are appointed by clinical priority and follow up adhere to NICE and BAD guidance for monitoring

Does your skin cancer pathway include remote patient-clinic interactions (as opposed to face-to-face
interactions), Yes or No and if yes, elaborate what they are and what stage in the pathway they're used e.g.,
teledermatology (the use of digital photography to assess patient lesions) at the GP stage.

We do not currently operate remote consultation for our suspected Skin cancer patients at Doncaster and Bassetlaw hospitals.

The GP practices have the option to use the Tele-dermatology which is not provided by the Trust and has been commissioned by the individual ICB's (previous CCG)

They are also able to utilise the ERS Advice and guidance at the Trust by supplying photos for clinical review

• What were your latest skin cancer pathway guidelines in 2019/2020 prior to the COVID-19 pandemic (announced as a pandemic by WHO on 11 March 2020).

DBTH pathway follows the NICE guidance for Skin cancer pathways and BAD recommendations

If possible, the preferred format of this information is electronic word document (.doc/.docx) or PDF.

